Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Daiichi Sankyo has announced that from 1st March 2020 Alliance Healthcare and Phoenix Healthcare Distribution will be the dual distributors for all Daiichi Sankyo UK Ltd products to pharmacies in the UK. You can read Daiichi Sankyo’s announcements to pharmacies via the Alliance Healthcare and Phoenix Healthcare Distribution notices. If you have questions regarding the...
The Centre for Pharmacy Postgraduate Education (CPPE) has launched a ‘New Year, New Contract’ campaign, which aims to raise awareness of the new Community Pharmacy Contractual Framework (CPCF) and the opportunities it brings for professionals in all sectors of pharmacy. The campaign will run for six weeks and each week will cover a different element...
As announced previously, Microsoft has now ended its free support, including security updates, for the Windows 7 operating system. This could put some systems at higher risk from viruses and other running problems. Community pharmacy contractors are recommended, with their IT/PMR support, to plan moving away from Windows 7, if that has not already been...
New NHS prescription forms and EPS Tokens are being introduced in England from January 2020. Changes have been made to the reverse of the new versions (1219) of all FP10 prescription types (FP10SS, FP10D, FP10PN, etc.), and Tokens (FP10DT), to make it easier for patients and pharmacy teams to determine whether the patient is eligible...
New NHS prescription forms and EPS Tokens are being introduced in England from January 2020. This Q&A style briefing is designed to help pharmacy teams understand the changes and adapt their processes accordingly to ensure patient declarations are captured accurately. PSNC Briefing 002/20: Changes to FP10 NHS prescription form and EPS Tokens These FAQs should...
The team at PSNC has received a number of queries on the Pharmacy Quality Scheme (PQS). Below are some of the questions asked in recent weeks. Q. I completed the CPPE risk management training and assessment over two years ago. Do I need to complete the training and assessment again? A. If you have completed...
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard. The draft quality standard calls for community pharmacy services to be included in existing care and referral pathways. This will allow community pharmacy teams to accept as well as make referrals to...
Update (17/01/2020): resupply date now expected mid/end February 2020 First published 20th December 2019 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Clonidine 25mcg tablets. Limited supplies of Clonidine 25mcg tablets will be available until at least mid-January 2020 due to manufacturing issues. The DHSC Medicine Supply Team provide...
Update (17/01/2020): resupply date now expected end January 2020 First published 15th November 2019 Issued: 14 November 2019 The Department of Health and Social Care (DHSC) have advised that Synphase tablets are out of stock until 20 December 2019. Other brands of phasic oral contraceptive tablets remain available during this period. Action required: For patients...
Update (17/01/2020) resupply date now March 2020 First published 15th November 2019 MSN/2019/007U, update to SDA/2019/002 Date issued 14th November DHSC have advised that Mylan, the sole supplier of disopyramide 150mg capsules, has had a delay to their resupply date. Mylan will be out of stock of Disopyramide 150mg capsules to approximately 13th December 2019....
Review Panel Annual Report 2018 - a panel that performs statutory and non-statutory reviews of proposals, decisions and provisional decisions taken by MHRA.
You must get permission to export certain drugs and medicines.
List of field safety notices (FSNs) from medical device manufacturers from 13 January to 17 January 2020
EAMS scientific opinion given to Aventis Pharma in the treatment of adult patients with relapsed and refractory multiple myeloma.
Guidance on sources of electromagnetic interference and mitigating the risks.
Information for clinicians and patients.
Manufactured by ConvaTec – specific batches of convex two-piece skin barriers have been incorrectly manufactured with off-centre starter/stoma hole.
How the ‘Written Confirmation’ process for active substances manufactured in the UK will be handled if there’s a no-deal Brexit.
Manufactured by Breas Medical Limited – maintenance schedule now includes changing the internal memory/alarm battery every 3 years.
MHRA investigation reveals illegally supplied opiate painkillers, tranquillisers and medications intended for the treatment of cancer worth £280,490.
Caution in Use: Distribute to Pharmacy level. Advanz Pharma has informed us of a discrepancy on the product packaging. The discrepancy relates to “capsules” printed at the top right of the packs in error, instead of tablets
List of field safety notices (FSNs) from medical device manufacturers from 06 to 10 January 2020.
Marketing authorisations granted in December 2019
Parallel import licenses granted in December 2019
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
How to join the phase I accreditation scheme.
List of field safety notices (FSNs) from medical device manufacturers from 30 December 2019 to 3 January 2020.
Expected time taken to process and grant a marketing authorisation or a variation to a marketing authorisation.
List of companies in the UK who have their licence to manufacture or wholesale medicines terminated and cancelled.
Details of seizure notice served to Guasco & Associates, Cheltenham. Published in January 2020
Details of the improvement notice served to St Paul's Veterinary Clinic, Kent. Published in January 2020
You must get permission to export certain drugs and medicines.
Guidance on applying for an authorisation to manufacture veterinary medicines.
This is the hub for all the Veterinary Medicines Directorate's communications on Brexit which includes guidance on how you can prepare.
Reporting against VMD published standards up to 31 December 2019.
New members appointed to serve on the Veterinary Products Committee from January 2020 until 31 December 2023
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Report of the ten products for which most Special Import and Special Treatment Certificates (SIC and STC) have been issued by VMD in the UK.
Product defect recall alert for Synulox Lactating Cow Intramammary Suspension - (Vm 42058/4143) by Zoetis UK Ltd
Details of the improvement notice served to Johnston Agri Supplies, Enniskillen, County Fermanagh. Published in October 2019.
The European Medicines Agency have issued advice for users of live PRRS vaccines.
Details of the improvement notice served to Alex the Vet, Uckfield, East Sussex. Published in December 2019.
Freedom of Information (FOI) requests received by the Veterinary Medicines Directorate (VMD) 1 January and 30 June 2019
Details of seizure notice served to SF Equine Vets Ltd, Maldon, Essex. Published in November 2019.
Validation during the Christmas period 2019 for an application for an MA, ManA, WDA, Batch Release and Export Certificate.
Details of seizure notice issued to NPD Ventures Ltd (T/A World of Pets) at the National Pet Show, NEC Birmingham Published November 2019
Guidance on applying to vary a veterinary Marketing Authorisation (MA).
The VMD telephone lines are now up and running.
Details of seizure notice issued to Pawfection Pets, Abertillery, Wales.
NICE is urging patients to ask their pharmacist advice about smoking, alcohol or maintaining a healthy weight.
The European Commission has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness in the disorders.
The partnership will have an initial focus on gene therapy applications of identified targets.
The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.
The approval was based on results from part one of the Phase III CASSIOPEIA study.
As it stands, damage to the macula can’t be reversed, making it the most common cause of permanent and severe sight loss in the UK.
The drug has been approved in combination with bendamustine and MabThera.
Breast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year.
Novartis also expects NICE and SMC decisions in the first half of 2020.
Of the 60 products in development, very few seem to show benefit over existing treatments.
The UK is "well on its way towards our ambition of zero HIV transmissions by 2030."
Due to the aging global population, recent years have seen an increased prevalence of chronic HF.
The 2020 PharmaTimes International Clinical Researcher of the Year will be closing for entry at midnight this Thursday the 23rd of January.
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
The plans were “ambitions”, and primary care is not being given the time, support and funding it needs.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
